Genmab company profile
Company profile
Genmab has 3,244 employees and is headquartered in Copenhagen, Denmark.
Founded in 1998 and based in Copenhagen, Denmark, Genmab works on antibody-based medicines for cancer and other diseases. Its marketed products include EPKINLY and TEPKINLY for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, Tivdak for recurrent or metastatic cervical cancer, and DARZALEX and DARZALEX FASPRO for multiple myeloma, and it has collaboration agreements with companies including AbbVie, Pfizer and Johnson & Johnson. Other products address lung cancer, multiple myeloma, multiple sclerosis and thyroid eye disease, and the pipeline spans solid tumors, ovarian cancer, sickle cell disease and hemophilia A.
In the fiscal year ended December 2025, revenue reached USD 3.7 billion, up 19.2% from the previous year, and net income was USD 963 million. The company had 3,244 employees and its headquarters are in Copenhagen. Its shares are also listed on NASDAQ.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Headquarters
- Carl Jacobsens Vej 30, 2500, Copenhagen
- Employees
- 3,244
- Chief executive
- Jan G.J. de Winkel
- Founded
- 1998
- Fiscal year
- January - December
- Listing
- GMAB · Nasdaq Copenhagen
- Currency
- DKK
- ISIN
- DK0010272202
- Website
- genmab.com
Genmab and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| GenmabGMAB | Denmark | $31.53B | 3,244 | 30.6% | 46.2 |
| UCBUCB | Belgium | $61.2B | 9,000 | 29.5% | 25.7 |
| Financière de TubizeTUB | Belgium | $11.78B | 3 | 0.0% | 109.0 |
| ALK-AbellóALK.B | Denmark | $8.09B | 2,773 | 26.9% | 40.7 |
| ABIVAXABVX | France | $7.61B | 98 | -6,270.4% | — |
| Bachem HoldingBANB | Switzerland | $6.92B | 2,725 | 21.8% | 39.2 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
